The etiology of bronchopulmonary dysplasia (BPD), a chronic lung disease of infants surviving respiratory distress syndrome, remains fundamentally enigmatic. BPD is decreasing in severity but continues to be a major problem in pediatric medicine, being especially prevalent among very premature infants. 
Introduction
Bronchopulmonary dysplasia (BPD), 1 a chronic inflammatory lung disease of premature infants (1), remains a major problem in pediatric medicine, paradoxically due to success in improving survival of preterm infants now that respiratory distress syndrome is routinely treated with prenatal glucocorticoids and surfactant replacement therapy (2) . It is estimated that 20% of ventilated newborns develop BPD (3), representing at least 3,000 infants annually in the USA (4) . In particular, from 1976 to 1990, the incidence of BPD increased from ‫ف‬ 10 to 33% in very low birth weight infants (1,500 grams or less). As a result, BPD now accounts for the highest mean health care costs per child and also is second only to asthma in terms of total health care costs per year in a given population (5) . However, this increase in BPD is not explained simply by the decrease in acute mortality in this population (2) . The pathophysiology of BPD is believed to be multifactorial, with factors contributing to lung injury believed to be trauma from mechanical ventilation, oxygen toxicity, infection, inflammation, and immaturity (4) . Improvements in medical management, especially high frequency ventilation, positive pressure ventilation using nasal prongs, surfactant replacement therapy, lower administered F i O 2 s, and careful monitoring and prompt treatment of infections, have reduced the severity of BPD occurring in human infants over the past decade (2, 4, 6, 7) . Although prenatal maturational therapy with dexamethasone, with or without postnatal surfactant therapy, has slightly lowered the overall incidence of BPD, it is controversial as to whether surfactant deficiency per se is a contributing factor (8, 9) . High dose surfactant alone has been found to have a more prolonged beneficial effect on oxygenation, with subsequent reduction in the incidence of BPD (10) . Beneficial effects of postnatal dexamethasone on BPD are likely to be due to generalized antiinflammatory effects of glucocorticoids. However, in spite of all of these advances, there is no biological marker for identifying which very low birth weight infants will go on to develop chronic lung disease (11).
Recently, BPD has been clinically defined as oxygen dependence at 28 d postnatal age or 36 wk after conception age, so we cannot draw exact parallels between the 6-to 10-d baboon model and the human disease. Nonetheless, there are close similarities in the apparent disease processes. In human hyaline membrane disease, numbers of cells containing pulmonary bombesin-like peptide (BLP) are low, due to either degranulation of NE cells and/or generalized epithelial cell necrosis. In lung sections from one of four infants with hyaline membrane disease, we previously detected marked elevation in BLP mRNA using in situ hybridization, suggesting that BLP might be implicated in the earliest stages of development of BPD (12) . Pulmonary NE cell hyperplasia, which represents predominantly a cell differentiation response (13) , occurs frequently in infants progressing to BPD (14, 15) . This observation could be relevant to the pathophysiology of BPD because BLP are known to be potent bronchoconstrictor peptides as well as growth factors for pulmonary fibroblasts and epithelial cells. Thus, early overproduction of BLP could mediate the peribronchiolar and interstitial fibrosis and reactive airways disease which are hallmarks of BPD. Although definitive testing of this hypothesis will require a clinical investigation, valuable insight can be gained from relevant animal models.
Although many species of rodents, nonhuman primates, and other laboratory animals develop acute hyaline membrane disease (HMD) (16) (17) (18) (19) (20) (21) (22) and even chronic interstitial lung disease similar to BPD (23) (24) (25) , preterm baboons comprise the best nonhuman animal model for both HMD and its chronic sequelae, which appears clinically and pathologically most similar to human BPD (26) (27) (28) (29) (30) (31) . The increasing incidence of BPD as one of the major unsolved problems in pediatric medicine resulted in the initiation of a collaborative program by the Na- PRN and requiring exogenous surfactant to survive, which is much more similar to the version of BPD currently seen in human infants (32). In this model of "new BPD," Ͼ 90% of 125-d/PRN animals develop characteristic clinical and pathological features of chronic lung disease found in ventilated extremely low birth weight human infants: mild interstitial and peribronchiolar fibrosis, chronic reactive airways disease, and especially arrested alveolar septation (31) .
Because infants with BPD have increased pulmonary NE cells containing BLP, a growth factor and bronchoconstrictor (15), we hypothesized that BLP mediates lung injury in BPD. The kinetics of BLP mRNA and peptide levels in normal baboon lung are similar to those in humans (Sunday, M.E., and R.L. Emanuel, manuscript in preparation). The present study demonstrates that urine BLP double between 24 and 72 h after birth in BPD animals, but not in controls. The severity of chronic lung disease correlates directly with this early increment in urine BLP. Blocking anti-BLP antibody administered to five BPD baboons soon after birth protects against histopathological changes of BPD. Although two of these baboons became septic, the others were clinically near normal. These observations suggest that elevated urine BLP might predict infants at highest risk for developing BPD, and blocking BLP after birth could be a novel treatment for preventing BPD.
Methods
Animals. The National Research Council Guide for the Care and Use of Laboratory Animals was strictly adhered to throughout all phases of this study. The Animal Care Committee of the Southwest Foundation for Biomedical Research reviewed and approved the protocols used in this study. Details of the neonatal intensive care unit (NICU) animal care have been described previously (29 /2A11). 2A11 murine monoclonal antibody (1 mg/ml, sterile, pyrogen-free, and azide-free) was administered intravenously as an infusion starting 2 h after birth (5 mg/kg, given over 2 h), with two boosts given similarly on days 3 and 6 (4 mg/kg, starting at ‫ف‬ 72 and 144 hours).
Urine BLP RIA. Urine was collected from newborn baboons as 24-h pooled specimens (5-50 ml total volume) which was stored at Ϫ 70 Њ C, shipped frozen on dry ice, and thawed only once at the time of assay, using an aliquot ( ‫ف‬ 1 ml) for RIA.
BLP levels were quantitated by RIA (Inc Star Corp., Stillwater, MN) using the clear supernatant of urine samples, containing 25 mM acetic acid and stored at Ϫ 70 Њ C. The assay uses a rabbit antibody to amphibian bombesin, has a detection limit of 100 pg/ml, and detects bombesin and its mammalian homologue gastrin-releasing peptide (GRP) which is the major known pulmonary BLP (12), but not related neuropeptides neuromedin B, substance P, nor neurotensin. Each sample was measured in at least two separate radioimmunoassays. Urine BLP values were normalized to their respective creatinine content (mg/ ml) which was measured using a kit (Sigma Chemical Co., St. Louis, MO) to correct for variations in urinary concentration or dilution. Each value shown on the plots represents a 24-h urine collection ending at the indicated time points; the normalized value for the first day urine collection is defined as 100%, with subsequent values expressed as the mean percent change compare to the 24-h urine BLP level.
Histopathological and immunohistochemical analyses. Tissues were fixed in 4% paraformaldehyde for 18 to 24 h before routine processing into paraffin, as described previously (33) . Histochemical stains included hematoxylin and eosin for general tissue architecture, Masson's trichrome for fibrosis, and elastin stain for demonstrating pulmonary alveolar architecture (34) .
Routine immunostaining was carried out on 3-m sections as described previously using PCNA monoclonal antibody clone PC10 (1:20 dilution) (Dako Corp., Carpinteria, CA) (33), our own rabbit antibombesin antisera (1:500 dilution) (35) , or rabbit polyclonal anti-PGP 9.5 (1:500 dilution) (Ultraclone Inc., Isle of Wight, UK) with the avidin-biotin complex (ABC) technique (Vector Laboratories, Burlingame, CA) (33) . The peroxidase substrate was diaminobenzidine and methyl green was used as the counterstain. Negative controls run in parallel consisted of the following: for PCNA, the isotype-matched MOPC-21 (IgG1) (Sigma Chemical Co.) was used; and for antibombesin antisera, bombesin antiserum preabsorbed overnight with bombesin antigen (10 g/ml) (36) .
Localization of 2A11 mouse monoclonal antibody in baboon tissues was carried out using a 1:10 dilution of biotinylated horse antimouse IgG (Vector Laboratories) as the primary antibody or biotinylated normal horse IgG as the negative control incubated overnight at 4 Њ C. Subsequent incubations with methanol/H 2 O 2 , the ABC reagent, and biotinylated tyramide (Tyramide-System Amplification [TSA] from Dupont-New England Nuclear, Boston, MA) were the same as for the standard immunoperoxidase method.
Statistical analyses. For group comparisons, statistical analyses used the Student's t test (unpaired), one-way ANOVA, or two-way ANOVA and results are given as mean values Ϯ SE.
Results
Changes in urine BLP levels predict BPD. Results of urine bombesin-like peptide (BLP) radioimmunoassay, normalized for creatinine to correct for variations in urinary concentration or dilution, are given in Fig. 1 . Control animals (140-d/PRN) had no significant change in mean urine BLP levels between 24 and 72 h after delivery ( n ϭ 9). Mild elevation in urine BLP levels occurred after Ն 96 h, consistent with increased numbers of pulmonary NE cells after prolonged mechanical ventilation (14) . Individual values from all nine animals are shown in Fig. 1 B , with all animals manifesting either a decline or minimal increase between 24 and 72 h after birth.
In contrast, the group of 140-d/100% O 2 baboons ( n ϭ 8) developing chronic lung disease similar to the original severe form of BPD had a significant doubling in mean urine BLP levels between 24 and 48 h, termed ⌬ urBLP (24-48) (Fig. 1 C ) . All of these animals manifested moderate to severe oxygenation impairment (oxygenation index [OI] Ͼ 2.5) and chest x-ray changes at 6 to 10 d of age, where OI is defined as (F i O 2 ϫ mean airway pressure) ϫ 100/P a O 2 . Although peaking at 48 h, urine BLP levels were still significantly elevated above the 24-h values at 72 and 96 h. Individual results from all eight of these animals are given in Fig In the five 140-d animals treated with 100% O 2 for which serial urine collections were available, there was a direct correlation ( r ϭ 0.93, P ϭ 0.022) between the increment in urine BLP between 24 and 48 h and the OI at 10 d (Fig. 1 F ) . There was no correlation between early changes in urine BLP (or absolute values of urine BLP at 24, 48, 72, or 96 h) and OI between 2 and 216 h of age (data not shown). In the 140-d/100% O 2 model, we did not observe any correlations between absolute urine BLP levels and OI, apparently due to variability in baseline urine BLP levels.
The above observations are based on the hyperoxic baboon model, and we cannot be absolutely certain that increased urinary BLP does not reflect increased BLP gene expression in response to hyperoxia rather than as a result of BPD per se. To provide assessment of changes in urine BLP and BPD independently of therapy with 100% O 2 , we also measured urine BLP levels in the second baboon model of "new BPD" (125-d gestation baboons treated with O 2 PRN and exogenous surfactant therapy) (30) . In this group ( n ϭ 12), there was a significant ( ‫ف‬ 30%) increase in urine BLP between 24 and 48 h after birth (Fig. 1 G ) , with doubling occurring at 72 h; levels remained elevated at 96 h. Most of these 125-d animals were maintained for only 6 d ( n ϭ 11), so that we could not analyze correlations with 10-d OI values. These observations suggest that elevated urine BLP levels might be associated with chronic lung disease occurring in diverse clinical settings.
In addition to its presence in lung, GRP mRNA can be detected in baboon brain, thyroid, stomach, and pancreas at 140 d gestation and after 100% O 2 treatment for 10 d (two animals screened, data not shown). It was also detected in thymus and/or adrenal in the two animals given 100% O 2 treatment for 10 d. Using reverse transcriptase-PCR (RT-PCR), we did not detect GRP mRNA in kidney or bladder. In previous studies of human fetal tissues, the major source of GRP mRNA and BLP immunoreactivity has been demonstrated to be lung (12) . We have obtained total RNA samples from lung of one 140-d animal given O 2 PRN for 24 h and another animal given 100% O 2 treatment for 24 h (thanks to Dr. Carl White, National Jewish Medical and Reaserch Center, Denver, CO). The animal treated with 100% O 2 had about a twofold increase in lung levels of GRP mRNA as compared to the PRN animal (data not shown). When we calculate the amount of BLP excreted in a 24-h urine collection ( ‫ف‬ 5 ng), it is less than half of the BLP content of lung tissue harvested from animals following 100% O 2 treatment for 10 d ( ‫ف‬ 14 ng). Thus, although we cannot be certain that the lung is the only source of urine BLP, the cumulative data are consistent with lung as the major contributor to urine BLP levels.
Postnatal treatment with anti-BLP-blocking antibody. To test whether BLP might play a causative role in the pathophysiology of BPD, we administered the well-characterized murine monoclonal anti-BLP-blocking antibody 2A11 to five 140-d/ 100% O 2 baboons beginning 2 h after birth. The dosage and frequency of administration were based on results from previous preclinical pharmacokinetics studies in mice and dogs (37): we chose a dose comparable to that required for Ͼ 95% blocking of BLP-triggered gastrin release in dogs. We sought objective evidence that 2A11 was indeed functioning as a BLP blocking antibody in the preterm baboons. First, the five 140-d/100% O 2 animals receiving 2A11 demonstrated only slightly elevated urine BLP at 48 h, which was not statistically significant compared to the 140-d/PRN controls; in contrast, 140-d/ 100% O 2 baboons which did not receive 2A11 had a significant doubling of urine BLP at 48 h (Fig. 2 A) . Results of BLP immunostaining of lung tissue sections from the five 2A11-treated baboons were similar to 140-d/100% O 2 animals which did not receive antibody (Fig. 2 , B-E): most BLP-positive neuroendocrine (NE) cells were localized to bronchioles (Fig. 2, B and D) and alveolar ducts (Fig. 2 E) . Specific immunostaining in thin serial sections was abrogated by preabsorption of antibody with bombesin antigen (Fig. 2 C) . Immunohistochemical analyses of postmortem tissue sections from all five 2A11-treated baboons using biotinylated horse anti-mouse IgG demonstrated the presence of mouse IgG predominantly in loose undifferentiated mesenchymal tissue around developing blood vessels and airways (Fig. 2 F) . This pattern of immunostaining is not observed when biotinylated normal horse IgG (same purity and concentration) is substituted for the horse anti-mouse IgG (Fig. 2 G) . These observations indicate that 2A11 administered systemically reaches the developing lungs, which are known to be rich in endogenous BLP derived from pulmonary NE cells (Fig. 2, B-E) (15) .
The mean oxygenation indices for the group of five 2A11-treated baboons are given in Fig. 3 and Table I , which also summarize parallel data from the negative control (140-d/ PRN, n ϭ 13) and positive control (140-d/100% O 2 , n ϭ 13) groups. The most striking immediate effect of the 2A11 infusion given 2 h after birth is marked improvement in mean OI between birth and 12 h of age (Fig. 3 A) . The data in Fig. 3 A clearly demonstrate a significant improvement in mean OI between 4 and 6 h after beginning the 2A11 infusion. This improved OI seen with 2A11 is sustained until 36 h of age (Fig. 3  B) compared to either 140-d/PRN or 140-d/100% O 2 animals, both of which develop acute respiratory distress syndrome similar to human hyaline membrane disease. Although there is also a trend towards improved OI at the 144-h time point, there is no significant difference in OI between the 2A11-treated animals and the other groups at later time points when the entire pool of animals is used for analysis. However, none of the five 2A11 animals developed an air leak (pneumothorax), in contrast to 4 of 13 140-d/100% O 2 "old BPD" positive controls (all female) and 4 of 13 140-d/PRN "no BPD" negative controls (two male, two female) (31% each group, see Table I). Also, none of the 2A11 animals required high frequency ventilation, in contrast to 46% of the 140-d/100% O 2 animals and 54% of the 140-d/PRN animals ( Table I ). All of these control animals (100% O 2 and PRN) were studied during the same time period as the 2A11-treated animals (1995-97), and therefore were subjected to the same intensive care unit procedures under the direction of a single neonatologist (Dr. Brad- 
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Clinical parameters relevant to the medical status of preterm infants are given. *The number of animals in each treatment group is given in parentheses. ‡ Whether or not animals were given 2A11 intravenously beginning 2 h after birth is indicated. § Birthweight is given in gramsϮSEM.
ʈ
The percentage of male animals in each group is given, with the total number of males given in parentheses. ¶ The percentage of animals requiring high frequency ventilation is given. **The percentage of animals developing clinical evidence of pneumothorax, requiring chest tube insertion, is given. ‡ ‡ Oxygenation Index (OI) at 240 h is given ϮSEM. ¶ ¶ P Ͻ 0.001 compared to 100% O 2 positive controls (one-way ANOVA). § § The change in urine BLP (normalized for creatinine) from 24 to 48 h is given. Urine specimens were not available on all animals. The number of animals analyzed is given in parentheses. There is minimal evidence of interstitial fibrosis (best appreciated with elastin stain in C), most of which occurs in areas with intraalveolar hemorrhage and/or resolving hyaline membrane disease (C, arrows). Although there is some evidence of airway and/or airspace dilatation, the magnitude of these changes is much less than that occurring in most animals not receiving 2A11. Pockets of alveolar hemorrhage and sparse neutrophilic infiltrates occur frequently in the vicinity of residual hyaline membranes (long arrows in D indicate intraalveolar hyaline membranes; short arrow indicates hyaline membrane phagocytosed by an alveolar macrophage). Although there is some perivascular fibrosis (V, arrow in D), there is minimal to no evidence of peribronchiolar fibrosis (aw, airway lumen) (D: hematoxylin and eosin). (E-H) Immunostaining of noninflated lung tissue slices fixed for 18-24 h with 4% paraformaldehyde. (E-G) PCNA immunostaining, carried out as described previously (33) To better understand potential factors contributing to these effects of 2A11, the OIs of the individual five 2A11-treated baboons were analyzed (Fig. 3 C) . The animal having the most severe acute RDS (4N96) was male, consistent with the known effects of androgens in delaying fetal lung maturation (38) and hence the higher incidence of surfactant deficiency and acute respiratory distress syndrome in boys (39) . Restricting our analysis to females only, 2A11-treated baboons (n ϭ 4) had a consistently improved clinical course over the 6 d of treatment compared to animals in both the 140-d/PRN (n ϭ 8) and 140-d/100% O 2 (n ϭ 7) treatment groups (Fig. 3 D) . It should be noted, however, that the RDS in the male baboon (4N96) did resolve and there was minimal evidence of chronic lung disease at 240 h in this animal.
Two of the female 2A11-treated animals (2Q96 and 6C96) developed late septicemia with acute pneumonia, leading to early death of one animal (2Q96). Although blood and sputum cultures were not positive in these animals being treated with multiple broad-spectrum antibiotics, profound leukopenia developed in parallel with altered hemodynamic parameters (markedly and suddenly decreased blood pressure that was refractory to therapy with volume and pressors), and was considered clinically pathognomonic of sepsis syndrome. Acute pneumonia represents a confounding factor that obscures clinical evidence for BPD. When analysis of the 5-10-d treatment interval was limited to animals without clinical evidence of septicemia (Fig. 3 E) , the three 2A11-treated animals (two females plus one male) had improved OI compared to 140-d/ 100% O 2 animals not receiving the antibody, which was significant at the 240-h time point (P Ͻ 0.001).
Histopathologically, after 10 d of 100% O 2 treatment, there was little evidence of BPD in the five animals receiving 2A11 (Fig. 4) . Low-power microscopic views of lung sections stained for elastic tissue demonstrated normal, well-developed alveolar architecture in 140-d/PRN animals (Fig. 4 A) versus extensive fibrosis with atelectasis and severe saccular overdistension in 140-d/100% O 2 baboons with moderate to severe BPD (Fig.  4 B) . However, the 140-d/100% O 2 baboons treated with 2A11 demonstrated only mild disruption of alveolar architecture (Fig. 4 C) , with some mild saccular overdistension and minimal interstitial thickening. On higher power microscopic examination of hematoxylin and eosin-stained sections (Fig. 4 D) and sections stained with the trichrome method for collagen deposition (data not shown), the lungs from 2A11-treated animals manifested no evidence of peribronchiolar fibrosis (Fig. 4 D) , which usually occurs as a characteristic feature of BPD (26, 27) . There were scattered areas with focal interstitial fibrosis associated with intraalveolar hemorrhage and sparse neutrophilic infiltrates, consistent with resolving hyaline membrane disease (Fig. 4, C and D, arrows) . Pathological evidence of intrapulmonary hemorrhage was present in a majority of both the 140-d/100% O 2 and the 140-d/PRN animals (all of which were ventilated and none of which received exogenous surfactant), and generally correlated with severity of acute RDS. Only the two animals which developed septicemia had more widespread, moderate to severe neutrophilic infiltrates, diagnostic of clinically significant acute pneumonia. Clinical and pathological evidence of septicemia typically occurs in Ͼ 5% of either 140-d/100% O 2 or 140-d/PRN animals (all of which had indwelling arterial lines).
Immunohistochemical analyses for proliferating cell nuclear antigen (PCNA) as a marker for proliferating cells revealed moderate labeling of predominantly the epithelial compartment in 140-d/PRN animals (Fig. 4 E) and intense labeling of both epithelium and distal lung mesenchyme in 140-d/100% O 2 baboons, consistent with ongoing interstitial fibrosis (Fig. 4  F) . In contrast, there was marked reduction in PCNA labeling of lung parenchyma in 2A11-treated animals (Fig. 4 G) , in which most of the residual proliferating cells were epithelial in location.
Discussion
The present study demonstrates that elevated urine BLP between 24 and 72 h after birth is a reliable predictor of which preterm baboons will develop chronic lung disease similar to BPD in two different baboon models of BPD. This effect is apparent even when gender is eliminated as a variable, and all experimental and control animals were treated during the same time frame under the direction of a single neonatologist to control for variations in intensive care unit practices. The precise mechanism for increased urinary BLP at the two different gestational ages with differing O 2 exposures is not known. Similarly, the precise pathophysiology of BPD is unknown: the role of immature antioxidant defenses in the 125-d PRN animals could undoubtedly play a role in the pathobiology of BPD in these extremely premature animals (32). Currently, there is no reliable epidemiological or biological marker for identifying which preterm human infants will go on to develop chronic lung disease (11). Furthermore, we demonstrate that postnatal administration of blocking anti-BLP antibody is protective against the development of clinical and pathological evidence of BPD: none of the five animals receiving anti-BLP blocking antibody manifested significant peribronchiolar fibrosis or widespread alveolar interstitial fibrosis. At least part of this effect is probably due to blockade of BLP function as a fibroblast growth factor, as evidenced by marked diminution in PCNA immunostaining in mesenchymal cells. Multiple molecular mechanisms underlying the anti-BLP antibody effect are likely, however, including decreased macrophage activation and blockade of direct effects of BLP as a bronchoconstrictor. It is unlikely that the late beneficial effect on the course of BPD is simply due to the early improvement in OI of anti-BLP antibody (2A11)-treated animals as compared to both the untreated 100% O 2 and O 2 PRN animals: the male 2A11-treated animal (4N96) did develop severe RDS, but had minimal evidence of chronic lung disease after 10 d of 100% O 2 .
Only a few potential adverse side effects of 2A11 are apparent. Histological analyses demonstrate scattered intraalveolar hemorrhages and sparse neutrophilic infiltrates in lung sections from all five 2A11-treated baboons, similar to 140-d/ 100% O 2 and 140-d/PRN animals, consistent with resolving hyaline membrane disease. This was most apparent in the male (4N96) after severe hyaline membrane disease which did resolve and did not appear to be correlated with adverse clinical outcome during the 10-d treatment period. A more serious potential side effect appears to be an increased incidence of septicemia. It is possible that BLP might be important for phagocytic and/or bactericidal function of macrophages and/or granulocytes, but further studies are required to address this hypothesis. We cannot completely exclude the possibility that the two baboons became septic by chance alone, especially considering the presence of indwelling arterial lines and endotracheal tubes in these preterm animals. Of additional note, cultures of the antibody stocks remaining were negative for bacterial and fungal organisms. Nonetheless, this is an unexpected, interesting scientific observation that may shed light on the role of bombesin-like peptides during acute and chronic lung injury processes.
One further point of interest concerns the significant improvement in OI in all five 2A11-treated animals during the first 36 h of postnatal life. In our previous work, we demonstrated that BLP is important for type II cell differentiation and surfactant synthesis as well as generalized cell proliferation in both murine and human fetal lung in organ culture and in murine lung in utero (40) (41) (42) (43) . Subsequent work in other laboratories confirmed and extended this result to isolated rat primary type II cell cultures (44, 45) , in which BLP stimulated surfactant secretion as well as synthesis (44) . The highest endogenous BLP levels occur at mid-gestation in primate lung, but often peak effects of BLP occur at subnanomolar concentrations (44, 45) . We postulate that 2A11 might promote more efficient secretion of endogenous surfactant from type II cells by reducing local BLP concentrations to a more optimal concentration. High doses of BLP often downregulate biological effects, regardless of whether the cellular response is proliferative, synthetic, or secretory. Finally, we cannot exclude the possibility that the 2A11 effect might be mediated via IgG1 Fc receptor function, with nonspecific modulation of macrophage function leading to altered cytokine production. Ideally, a double-blinded, randomized baboon trial should be carried out using 2A11 versus MOPC, an IgG1 of undefined specificity, to control for nonspecific IgG effects. The prohibitive expense and limited numbers of animals available for these studies have precluded carrying out these rigorous controls using the 140-d/100% O 2 model. Follow-up studies are aimed at indepth analyses with a paired irrelevant IgG1 murine monoclonal antibody control using the more clinically relevant 125d/ PRN model for mild-to-moderate BPD, which is most similar clinically and pathologically to current cases of human BPD.
These studies introduce the interesting concept of pulmonary NE cells as a component of the inflammatory response. We have demonstrated that cytokines such as TNF-␣ can induce neuroendocrine cell differentiation in human small cell lung cancer cell lines (46) , which could explain the increased number of these cells in the lung of guinea pigs immunized systemically with ovalbumin (47) . This would suggest that BPD might be viewed as an inflammatory response gone awry, and points to possible clinical usefulness of agents for blocking BLP receptor signaling during lung injury.
